Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...

Biohaven Ltd. (NYSE:BHVN) is one of the best low priced pharma stocks to buy now. Earlier on June 10, Bexorg Inc., which is a techbio company focused on central nervous system/CNS disorders, announced ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...

Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as ...

Despite warnings, potentially inappropriate CNS-active medications are commonly prescribed to older adults — especially those with cognitive impairment — highlighting missed opportunities for safer ...

Nanotechnology has and continues to rapidly advance the field of drug delivery, especially in HIV therapy. The use of NPs is helping to improve the pharmacokinetics of old drugs and is finding new ...

Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in ...

This episode of the Pharmaron DMPK Insights Podcast Series sees Scott Summerfield (Senior Director and Head of Pharmaceutical Metabolism at Pharmaron) and Professor Elizabeth de Lange Professor in ...